Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome
| العنوان: | Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome |
|---|---|
| المؤلفون: | Uche Ezeh, Melanie Landay, Ricardo Azziz, Andy Huang |
| المصدر: | Journal of Women's Health. 27:892-902 |
| بيانات النشر: | Mary Ann Liebert Inc, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Hirsutism, medicine.medical_specialty, Combination therapy, 030209 endocrinology & metabolism, Spironolactone, Menstrual irregularity, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Sex Hormone-Binding Globulin, Internal medicine, medicine, Humans, hirsutism, Acne, Mineralocorticoid Receptor Antagonists, Retrospective Studies, 030219 obstetrics & reproductive medicine, business.industry, Original Articles, General Medicine, medicine.disease, Polycystic ovary, Long term response, Cross-Sectional Studies, Treatment Outcome, chemistry, Improvement rate, Drug Therapy, Combination, Female, Hyperandrogenism, business, Contraceptives, Oral, Polycystic Ovary Syndrome |
| الوصف: | Background: Polycystic ovary syndrome (PCOS) affects 5%–15% of women and is the most common cause of hirsutism. Data on the time-course of improvement to suppressive therapy and predictors of that response in PCOS are lacking. The objectives of our study are to determine the long-term response and identify predictors of response in PCOS women treated with suppressive therapy, including spironolactone (SPL) + oral contraceptives (OCs). Materials and Methods: Retrospective cross-sectional analysis of 200 women with PCOS (1990 NIH criteria) treated with suppressive therapy in general, and a subgroup of 138 subjects treated with OCP+SPL who had been prospectively included in a biorepository. Main outcome measure included improvement rate per 100 person-month of follow-up for hirsutism, menstrual irregularity and acne measured qualitatively as “feeling better”, and changes in the severity of hirsutism quantified by modified Ferriman-Gallwey [mF-G] score. Results: During a mean follow-up of 34.2 months, 85.1%, 82.7%, and 79.3% of patients reported improvement in hirsutism, menstrual dysfunction, and acne, respectively. The modified Ferriman–Gallwey (mF-G) hirsutism score improved by 59.9%. The net reduction in mF-G score and the percent of patients reporting improvement in hirsutism were greater for OC+SPL than for either drug alone, with no difference in the percent of patients free of adverse effects. Among those treated with OC+SPL (n = 138), the initial mF-G and sex hormone-binding globulin (SHBG) independently predicted successful therapy for hirsutism. Conclusion: There is a high rate of patient satisfaction with suppressive therapy in PCOS. The efficacy of suppressive therapy for hirsutism was greater with OC+SPL than with either drug alone. Successful treatment of hirsutism with combination OC+SPL requires at least 6 months of therapy, with the proportion of satisfied patients continuing to increase with treatment duration. The probability of patient satisfaction with OC+SPL treatment for hirsutism can be predicted by her initial mF-G score or SHBG level. |
| تدمد: | 1931-843X 1540-9996 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32cb8763c38a9950af3a72c362576aaTest https://doi.org/10.1089/jwh.2017.6833Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b32cb8763c38a9950af3a72c362576aa |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1931843X 15409996 |
|---|